InnoCare's Oral TYK2 Inhibitor Soficitinib Meets Primary Endpoint in Phase II Trial for Non-Segmental Vitiligo

July 16, 2025

Beijing InnoCare Pharma Tech Co., Ltd. had reason to celebrate Wednesday. The Chinese biotech announced that its experimental oral drug soficitinib met the primary endpoint in a Phase II study for adult non-segmental vitiligo, marking a significant milestone in the company's push to carve out a position in the competitive autoimmune-disease market.

Soficitinib, also known as ICP-332, is a next-generation oral TYK2 inhibitor — a targeted therapy designed to modulate T-cell activity, which plays a central role in autoimmune conditions. The drug is self-developed by InnoCare and is being evaluated across a broad pipeline of T-cell-mediated diseases.

Strong Efficacy Signals

The Phase II/III study is a randomized, double-blind, placebo-controlled, parallel-group, adaptive, multicenter clinical trial. The Phase II portion evaluated soficitinib's efficacy in adult patients with non-segmental vitiligo.

At Week 24, the results were striking. Patients receiving 80 mg of soficitinib once daily saw their Facial Vitiligo Area Scoring Index, or F-VASI, improve by 38.8% from baseline. The 120 mg once-daily group achieved a 41.2% improvement. By contrast, the placebo group showed only a 2.2% change.

Both dose groups demonstrated statistically significant differences versus placebo, with a P-value of less than 0.0001 — a level of confidence that rarely appears in early-stage dermatology trials.

Safety Profile Consistent

InnoCare said soficitinib demonstrated a favorable safety profile consistent with prior clinical studies. No new safety signals were observed, and the drug was generally well tolerated across both dose groups.

A Broad Pipeline Bet

Beyond vitiligo, InnoCare is positioning soficitinib as a platform drug for multiple T-cell-related autoimmune diseases. The company's pipeline includes trials or plans for atopic dermatitis, prurigo nodularis, urticaria, and psoriasis — all conditions driven by dysregulated T-cell immune responses.

The TYK2 inhibitor class has attracted significant industry attention in recent years. Bristol Myers Squibb's deucravacitinib, the first oral TYK2 inhibitor approved by the U.S. Food and Drug Administration, won approval for plaque psoriasis in 2022. InnoCare's bet is that soficitinib's high selectivity and oral convenience can capture share across a wider set of indications.

With Phase II data in hand, InnoCare now moves into the pivotal Phase III stage for vitiligo — the make-or-break step that will determine whether the drug can reach patients. The results will also inform the company's broader strategy of building a TYK2 franchise across autoimmune disease.